Pharmacoeconomics

 

Delivering improved mechanistic insight and predictive power early

in development is HμREL^®’s fundamental benefit.  It has material economic import: 

• reducing the incidence of super-costly late-stage failures by “failing early”;
• accelerating time-to-market and the start of product revenues;
• reducing the drug developer’s total cost of capital invested per candidate;
• expanding the period of proprietary revenue generation prior to patent expiry;
• increasing the quality and monetizable value of the drug development pipeline.

 

Of the over $1 billion fully burdened cost of developing one new drug, HμREL^® estimates the aggregate benefit of the above impacts at around $100 million.